Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cue Biopharma (CUE) Operating Income (2018 - 2025)

Historic Operating Income for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to -$7.6 million.

  • Cue Biopharma's Operating Income rose 1384.0% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.2 million, marking a year-over-year increase of 1649.09%. This contributed to the annual value of -$41.5 million for FY2024, which is 2042.03% up from last year.
  • Per Cue Biopharma's latest filing, its Operating Income stood at -$7.6 million for Q3 2025, which was up 1384.0% from -$8.6 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Operating Income registered a high of -$7.6 million during Q3 2025, and its lowest value of -$14.9 million during Q4 2022.
  • Over the past 5 years, Cue Biopharma's median Operating Income value was -$12.3 million (recorded in 2025), while the average stood at -$11.5 million.
  • In the last 5 years, Cue Biopharma's Operating Income plummeted by 8834.24% in 2022 and then soared by 3035.71% in 2024.
  • Cue Biopharma's Operating Income (Quarter) stood at -$7.9 million in 2021, then tumbled by 88.34% to -$14.9 million in 2022, then rose by 6.96% to -$13.8 million in 2023, then surged by 30.36% to -$9.6 million in 2024, then grew by 21.16% to -$7.6 million in 2025.
  • Its last three reported values are -$7.6 million in Q3 2025, -$8.6 million for Q2 2025, and -$12.3 million during Q1 2025.